ACADIA Pharmaceuticals Inc. (ACAD) P/E Ratio History
UndervaluedTrading at 11.4x vs 5Y avg 18.1x · 45th percentile · Below historical baseline · Data 2010–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, ACADIA Pharmaceuticals Inc. (ACAD) trades at a price-to-earnings ratio of 11.4x, with a stock price of $26.20 and trailing twelve-month earnings per share of $2.18.
The current P/E is 37% below its 5-year average of 18.1x. Over the past five years, ACAD's P/E has ranged from a low of 4.4x to a high of 90.3x, placing the current valuation at the 45th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, ACAD trades at a 51% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, ACAD trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ACAD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ACAD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ACAD P/E vs Peers
Neuroscience and Psychiatry Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.7Lowest | 0.65 | +817%Best | |
| $2B | 9.9 | 0.06Best | +40% | |
| $7B | 11.5 | - | +264% | |
| $30B | 23.3 | - | -21% | |
| $9B | 38.6 | - | -34% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ACAD Historical P/E Data (2010–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $22.26 | $2.20 | 10.1x | -44% |
| FY2025 Q3 | - | $21.34 | $1.55 | 13.8x | -24% |
| FY2025 Q2 | Jun 30 2025 | $21.57 | $1.33 | 16.2x | -11% |
| FY2025 Q1 | Mar 31 2025 | $16.61 | $1.37 | 12.1x | -33% |
| FY2024 Q4 | - | $18.35 | $1.36 | 13.5x | -26% |
| FY2024 Q3 | Sep 30 2024 | $15.38 | $0.78 | 19.7x | +9% |
| FY2024 Q2 | Jun 30 2024 | $16.25 | $0.18 | 90.3x | +398% |
| FY2011 Q3 | Sep 30 2011 | $1.08 | $0.24 | 4.4x | -76% |
| FY2011 Q2 | - | $1.63 | $0.23 | 7.1x | -61% |
| FY2011 Q1 | - | $1.62 | $0.24 | 6.8x | -63% |
| FY2010 Q4 | Dec 31 2010 | $1.20 | $0.22 | 5.5x | -70% |
Average P/E for displayed period: 18.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
16+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ACAD — Frequently Asked Questions
Quick answers to the most common questions about buying ACAD stock.
What is ACAD's P/E ratio?
ACADIA Pharmaceuticals Inc. (ACAD) trailing twelve-month P/E ratio is 11.4x, based on TTM diluted EPS of $2.18. The 5-year average P/E is 18.1x and the historical range spans 4.4x to 90.3x.
Is ACAD stock overvalued or undervalued?
ACAD trades at 11.4x P/E, below its 5-year average of 18.1x. At the 45th percentile of its historical range (4.4x–90.3x), the stock is priced at a discount to its own history.
Is ACAD stock expensive?
No, ACAD is not expensive on a historical basis. The current P/E of 11.4x is below the 5-year average of 18.1x and sits at the 45th percentile of its valuation range.
What is ACAD's historical P/E range?
Over the past 5 years, ACAD's P/E ratio has ranged from 4.4x to 90.3x, with a median of 12.1x and an average of 18.1x. The current P/E of 11.4x places the stock at the 45th percentile of this range. Full historical data spans 2010–2026.
How does ACAD's P/E compare to the S&P 500?
ACAD trades at 11.4x P/E versus the S&P 500 median of 25.9x. The 56% discount to the market suggests lower growth expectations or perceived higher risk.
How does ACAD's valuation compare to Healthcare peers?
ACADIA Pharmaceuticals Inc. P/E of 11.4x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ACAD's PEG ratio?
ACAD PEG ratio is N/A, based on a P/E of 11.4x and EPS growth of 68.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ACAD's earnings yield?
ACAD earnings yield is 8.74%, the inverse of its 11.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.